HGS cheered by mid-stage lupus data

Human Genome Sciences is touting mid-stage data that shows its lupus treatment significantly reducing disease activity. LymphoStat-B reduced disease activity after 52 weeks of therapy and more than 95 percent of the patients in the trial signed on for a new study of the therapy. Investigators will now focus on patients response rates as a primary endpoint in Phase III.

- check out this release on the data
- read the AP report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.